NKTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nektar Therapeutics is not a strong buy for a beginner, long-term investor at the moment. Despite positive analyst sentiment and recent clinical data, the company's financial performance is weak, hedge funds are selling, and there is no strong signal from proprietary trading tools. The stock's pre-market price is slightly down, and the options data suggests neutral sentiment. Given the investor's preference for long-term growth and the lack of immediate strong catalysts, it is better to hold off on buying NKTR at this time.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (1.339), indicating a bullish trend. RSI is neutral at 60.065, and the stock is trading near its pivot level of 90.978. Key resistance levels are at 103.39 and 111.057, while support levels are at 78.567 and 70.9.
Positive clinical trial data for rezpegaldesleukin in alopecia areata and atopic dermatitis.
Analysts have raised price targets significantly, with multiple Buy ratings.
Successful public offering raising $373.8 million, reflecting market confidence.
Hedge funds are selling heavily, with a 1229.84% increase in selling last quarter.
Weak financial performance in Q4 2025, with revenue down 25.25% YoY, net income down 596.89% YoY, and EPS down 440.38% YoY.
No recent congress trading data or significant insider activity.
In Q4 2025, Nektar's revenue dropped by 25.25% YoY to $21.81 million. Net income plummeted by 596.89% YoY to -$36.08 million, and EPS fell by 440.38% YoY to -1.77. However, gross margin improved to 100%, up 37.63% YoY.
Analysts are generally positive on Nektar, with multiple Buy ratings and significant price target increases. Recent targets include $151 (Citi), $185 (H.C. Wainwright), and $150 (B. Riley). Analysts are optimistic about the company's clinical data and market potential for rezpegaldesleukin, but some remain cautious about market penetration in specific programs.
